Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of PCV13 in HIV-infected Adults
NCT03838497Phase 4Completed
- Sponsor
- Korea University Guro Hospital
- Start
- Apr 2015
- Primary completion
- Jan 2017
- Modality
- Split/Subunit Vaccines
01
Overview
Phase 4, open-label trial of pneumococcal 13-valent conjugate vaccine in Pneumococcal pneumonia (PP) (2 arms), sponsored by Korea University Guro Hospital. Primary endpoint: Opsonophagocytic assay titers for PCV13 at 28 days. Started Apr 2015; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
Pneumococcal pneumonia (PP)
Beyond the preview
Go deeper on NCT03838497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03838497.